Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease

BJU International

Volumn 110, Issue 6, 2012, Pages 821-827

  Corcoran, Niall M ^a,b   Hovens, Chris M ^b   Metcalfe, Charles ^a   Hong, Matthew K H ^b   Pedersen, John ^c   Casey, Rowan G ^a   Peters, Justin ^b   Harewood, Laurence ^b   Goldenberg, S Larry ^a   Costello, Anthony J ^b   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Tissupath Pty Ltd   (Australia)

Author keywords

biochemical recurrence; positive surgical margins; risk stratification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT TOOL; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CODING; POSITIVE SURGICAL MARGIN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; UNIVARIATE ANALYSIS;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84865509899     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10868.x     Document Type: Article

References (22)

1. Karakiewicz PI, Eastham JA, Graefen M, et al,. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 1245-50
2. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT,. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-24
3. Ahyai SA, Zacharias M, Isbarn H, et al,. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. BJU Int 2010; 106: 478-83
4. Vis AN, Schroder FH, van der Kwast TH,. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 2006; 50: 258-65
5. Swindle P, Eastham JA, Ohori M, et al,. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2008; 179: S47-51
6. Pfitzenmaier J, Pahernik S, Tremmel T, Haferkamp A, Buse S, Hohenfellner M,. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int 2008; 102: 1413-8
7. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400
8. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-34
9. Boorjian SA, Karnes RJ, Crispen PL, et al,. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 2010; 183: 1003-9
10. Simmons MN, Stephenson AJ, Klein EA,. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-84
11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
12. Daskivich TJ, Regan MM, Oh WK,. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176: 1927-37
13. Antonarakis ES, Chen Y, Elsamanoudi SI, et al,. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2010; 108: 378-85
14. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
15. Stephenson AJ, Scardino PT, Kattan MW, et al,. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41
16. Lee AK, D'Amico AV,. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005; 23: 8192-7
17. Bolla M, van Poppel H, Collette L, et al,. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8
18. Thompson IM Jr, Tangen CM, Paradelo J, et al,. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35
19. Van der Kwast TH, Bolla M, Van Poppel H, et al,. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-86
20. Alkhateeb S, Alibhai S, Fleshner N, et al,. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010; 183: 145-50
21. Corcoran NM, Hong MK, Casey RG, et al,. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 2011; 108: E202-10
22. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22